BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17957102)

  • 1. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
    Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum CA125 level before the development of ovarian cancer.
    Kobayashi H; Ooi H; Yamada Y; Sakata M; Kawaguchi R; Kanayama S; Sumimoto K; Terao T
    Int J Gynaecol Obstet; 2007 Nov; 99(2):95-9. PubMed ID: 17643440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
    Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I
    Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer.
    Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M
    Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study.
    Funston G; Hamilton W; Abel G; Crosbie EJ; Rous B; Walter FM
    PLoS Med; 2020 Oct; 17(10):e1003295. PubMed ID: 33112854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project.
    Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S;
    Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2000 Feb; 107(2):165-9. PubMed ID: 10688498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study.
    Bosse K; Rhiem K; Wappenschmidt B; Hellmich M; Madeja M; Ortmann M; Mallmann P; Schmutzler R
    Gynecol Oncol; 2006 Dec; 103(3):1077-82. PubMed ID: 16904167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors influencing serum CA125II levels in healthy postmenopausal women.
    Pauler DK; Menon U; McIntosh M; Symecko HL; Skates SJ; Jacobs IJ
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):489-93. PubMed ID: 11352859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of screening for ovarian cancer: a multicenter study in Japan.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T
    Int J Gynecol Cancer; 2008; 18(3):414-20. PubMed ID: 17645503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening.
    Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A
    In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer screening in women with a family history of breast or ovarian cancer.
    Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P
    Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-operative prediction of serum CA125 level in women with ovarian masses.
    Benjapibal M; Neungton C
    J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
    Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
    J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
    Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
    Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Program for early detection of ovarian cancer for women as prophylaxis provided at a municipal hospital].
    Cnota W; Sodowski K; Olesiak-Andryszczak M; Pilch-Kowalczyk M
    Wiad Lek; 2004; 57 Suppl 1():43-7. PubMed ID: 15884203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.
    Drescher CW; Nelson J; Peacock S; Andersen MR; McIntosh MW; Urban N
    Cancer Epidemiol Biomarkers Prev; 2004 Apr; 13(4):600-6. PubMed ID: 15066925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.